Comparison of the bone turn-over markers in patients with multiple sclerosis and healthy control subjects

European Journal of Inflammation

Volumn 8, Issue 2, 2010, Pages 67-73

  Hossein nezhad, Arash ^a   Khoshniat Nikoo, M ^a   Mirzaei, K ^a   Mokhtarei, F ^a   Aghaei Meybodi, H R ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bone mineral density; Bone turnover; Cross laps; Multiple sclerosis; Osteocalcin

Indexed keywords

CALCIFEDIOL; CORTICOSTEROID; OSTEOCALCIN; PARATHYROID HORMONE;

ADULT; ARTICLE; BONE DENSITY; BONE TURNOVER; CASE CONTROL STUDY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE PREDISPOSITION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HIP; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OSTEOLYSIS; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; REGISTER; SPINE;

EID: 80053520363     PISSN: 1721727X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1721727X1000800203     Document Type: Article

References (26)

1. Comabella M, Pericot I, Goertsches R, Nos C, Castillo M, Blas Navarro J, Río J, Montalban X. Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol 2005; 158:231-9. (Pubitemid 39626091)
2. Freedman MS. Disease-modifying drugs for multiple sclerosis current and future aspect. Expert Opin Pharmacother 2006; 7(S):1-9.
3. Dean G. How many people in the world have multiple sclerosis?. Neuroepidemiology 1994; 13:1-7. (Pubitemid 24107445)
4. Stepan JJ, Havrdová E, Týblová M, Horáková D, Tichá V, Nováková I, Zikán V. Markers of bone remodeling predict rate of bone loss in multiple sclerosis patients treated with low dose glucocorticoids. Clin Chim Acta 2004; 348:147-54. (Pubitemid 39209013)
5. Tofighi P, Hossein-Nezhad A, Sedighi N, Maghbooli ZH, Larijani B. Vertebral geometry parameters can predict fractures. Iranian J Pub Health 2007; (S):14-23.
6. Hossein-nezhad A, Ahangari G, Larijani B. Evaluating of VDR gene variation and its interaction with immune regulatory molecules in osteoporosis. Iranian J Pub Health 2009; 38:27-36.
7. Schwid S, Goodman A, Puxos J, McDermott M, Mattson D. Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis. Arch Neurol 1996; 53:753-7. (Pubitemid 26266920)
8. Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M. Effects of intravenous methylprednisolone on brain atrophy in relapsing-remitting multiple sclerosis. Neurology 2001; 57:1239-47.
9. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J. The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int 2000; 11(S):2-17.
10. Eshaghi SM, Hossein-nezhad A, Maghbooli Z, Larijani B. Relationship between Mandibular BMD and Bone Turnover Markers in Osteoporosis Diagnosis. Iranian J Pub Health 2008; (S):63-71.
11. Maghbooli Z, Hossein-Nezhad A, Nikoo MK, Shafei AR, Rahmani M, Larijani B. Bone marker status in mothers and their newborns in Iran. J Mat-Fetal Neonat Med 2007; 20:639-43. (Pubitemid 47262700)
12. Roudsari AH, Tahbaz F, Hossein-Nezhad A, Arjmandi B, Larijani B, Kimiagar SM. Assessment of soy phytoestrogens' effects on bone turnover indicators in menopausal women with osteopenia in Iran: a before and after clinical trial. Nutr J 2005; 29:4-30.
13. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50:121-7.
14. Shuhaibar M, McKenna MJ, Au-Yeong M, Redmond JM. Favorable effect of immunomodulator therapy on bone mineral density in multiple sclerosis. Ir J Med Sci 2009; 178:43-5.
15. Zorzon M, Zivadinov R, Locatelli L, et al. Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis. Eur J Neurol 2005; 12:550-6. (Pubitemid 40956813)
16. Nieves J, Cosman F, Herbert J, Shen V, Lindsay R. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 1994; 44:1687-92. (Pubitemid 24286648)
17. Kampman MT, Steffensen LH. Comment on Shuhaibar et al.: Favourable effect of immunomodulator therapy on bone mineral density in multiple sclerosis. Ir J Med Sci 2009; 178:235-6.
18. Cosman F, Nieves J, Herbert J, Shen V, Lindsay R. High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. J Bone Miner Res 1994; 9:1097-105. (Pubitemid 24191798)
19. Slatopolsky E, Brown AJ. Vitamin D analogs for the treatment of secondary hyperparathyroidism. Blood Purif 2002; 20:109-12. (Pubitemid 34102516)
20. Uzawa T, Hori M, Ejiri S, Ozawa H. Comparison of the effects of intermittent and continuous administration of human parathyroid hormone(1-34) on rat bone. Bone 1995; 16:477-84.
21. Bonadonna S, Burattin A, Nuzzo M, et al. Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects. Europ J Endocrinol 2005; 152:199-205. (Pubitemid 40309565)
22. Saghafi H, Hossein-nezhad A, Sedighi N, Tofighi P, Soltani A, Larijani B, Hafezi R. Osteoimmunological insight into vertebral fractures in osteoporosis. Iranian J Pub Health 2008; (S):7-15.
23. Yao W, Cheng Z, Busse C, Pham A, Nakamura MC, Lane NE, Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum 2008; 58:1674-86. (Pubitemid 351847520)
24. Weinstein RS, Chen JR, Powers CC, Stewart SA, Landes RD, Bellido T, Jilka RL, Parfitt AM, Manolagas SC. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Investig 2002; 109:1041-8. (Pubitemid 34408579)
25. Kim HJ, Zhao H, Kitaura H, et al. Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 2006; 116:2152-60. (Pubitemid 44162324)
26. Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann NY Acad Sci 2002; 966:73-81. (Pubitemid 34729163)